Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AST SpaceMobile Inc (ASTS) vs TG Therapeutics Inc (TGTX) Price & Performance

AST SpaceMobile IncTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

AST SpaceMobile Inc vs TG Therapeutics Inc — how do they compare? AST SpaceMobile Inc trades at $74.3 (market cap $20.54B), while TG Therapeutics Inc trades at $49.58 (market cap $7.64B). The key difference: AST SpaceMobile Inc is far larger — about 2.7× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, AST SpaceMobile Inc nearer its low. Which is the better fit depends on your goals.

ASTSTGTX
Market Cap
$20.54B$7.64B
Sector
MediaHealth
52-Week High
$133.09$59.06
52-Week Low
$36.91$26.94
Enterprise Value
$21.25B$7.84B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AST SpaceMobile Inc

AST SpaceMobile (ASTS) trades at $74.01, up 7.64% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical signal with key resistance at $77. Fundamentally, revenue grew to $70.92M in 2025 but profitability remains challenged with a -573.67% net margin. The company is expanding its satellite network with SpaceX support and maintains a $1.2B-$1.3B backlog.

Outlook remains speculative with significant cash burn and execution risks, but potential exists if commercial service scales successfully. Analyst consensus targets $84.63 with mixed ratings. Key risks include sustained losses, capital intensity, and competitive pressure in the emerging satellite connectivity market.

TG Therapeutics Inc

TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.

The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AST SpaceMobile Inc

AST SpaceMobile Inc is a satellite designer and manufacturer. The company is building the global cellular broadband network in space to operate directly with standard, unmodified mobile devices based on extensive IP and patent portfolio. AST is on a mission to eliminate the connectivity gaps faced by mobile subscribers and finally bring broadband to the billions who remain unconnected.

Read more on ASTS

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX